Comprehensive analysis of the regional dynamics shaping the market; and Exhaustive assessment of the key market players and their dominant strategies. Hemophilia is a rare bleeding disorder that is ...

PARAMUS, N.J., July 26, 2023 – Octapharma USA today announced that Balfaxar ® (prothrombin complex concentrate, human-lans; marketed in Europe and Canada as octaplex ®) has received U.S. Food and Drug ...

In patients experiencing excessive bleeding during cardiac surgery, a concentrated blood product containing proteins that help the blood clot was significantly more effective and caused fewer adverse ...

Please provide your email address to receive an email when new articles are posted on . Treatment with four-factor prothrombin complex concentrate was superior to plasma for the urgent reversal of ...

RARITAN, N.J., July 2, 2013 /PRNewswire/ -- Janssen Research & Development, LLC (Janssen) announced today results of an open label, single-center, parallel group study showing that a type of ...

Early administration of 4-factor prothrombin complex concentrate (4F-PCC) was of no benefit to patients with trauma at risk of massive transfusion, the randomized PROCOAG trial from France showed.

The 94.3% efficacy of the Octapharma product was just a shade ahead of the 94.2% measured in a comparative product, Kcentra. Results of a Phase III study (LEX-209) of the safety and efficacy of ...

Prothrombin complex concentrates (PCCs) are faster and more effective than fresh frozen plasma at reversing hemorrhage caused by the anti-coagulant warfarin, despite plasma being the most commonly ...

For patients who experience excessive bleeding during cardiac surgery, four-factor prothrombin complex concentrate (4F-PCC), a blood product that contains clotting factors, is significantly more ...

About The Study: In this unblinded randomized clinical trial, prothrombin complex concentrate had superior hemostatic efficacy and safety advantages to frozen plasma among patients requiring ...